ACM
YMAB

AIGH Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

AIGH Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-428,412
Closed -$2.15M – 56
2023
Q1 		$2.15M Buy
+428,412
New +$1.75M 0.79% 31

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AIGH Capital Management's YMAB Position: Q2 2023 in Review

AIGH Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q2 2023, closing a stake of 428,412 shares — an estimated $2.15M sold.

AIGH Capital Management first reported a position in YMAB in Q1 2023 and held it in 1 quarter. The position peaked at $2.15M in Q1 2023. 95 funds tracked by Wall St. Rank hold YMAB as of Q2 2023.

  • AIGH Capital Management reported no remaining Y-mAbs Therapeutics position as of Q2 2023 after selling out during the quarter.
  • AIGH Capital Management sold 428,412 Y-mAbs Therapeutics shares in Q2 2023, an estimated $2.15M.
  • AIGH Capital Management first reported a position in Y-mAbs Therapeutics in Q1 2023 and held it in 1 quarter.
  • AIGH Capital Management's Y-mAbs Therapeutics position peaked at $2.15M in Q1 2023.
  • 95 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2023.

Based on AIGH Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.